LGND

#3926
Ligand Pharmaceuticals Incorporated - Common Stock
2.3 2 USD
-99.01%
Setor: Cuidados de saúde
Base: USD
Moeda do lucro: USD
Faixa diária
2.32
2.32
Faixa anual
2.29
247.38
Mudança diária
-99.01%
Mudança mensal
-98.97%
Mudança em 6 meses
-98.84%
Mudança anual
-98.76%
Fechamento anterior
234.6 6
Open
2.3 2
Mínimo
2.3 2
High
2.3 2
Volume
61
Abrir gráfico completo Full chart

Financials

Visão geral Relatórios Estatísticas Dividendos
Trimestral Ano
Demonstração de resultados Balanço patrimonial Fluxo de caixa
Valor Q4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26 TTM

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol. The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments. Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020.

Notícias